Patients to be enrolled in final
stage of
Boston clinical trial for Endostatin™
Boston Hospitals’ Phase I Study Coming To A Close
BOSTON — July 10, 1999 — During the next several weeks, clinical researchers at Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center will enroll 12 patients into the final stage of their Endostatin clinical trial. Once these patients have been enrolled, the Phase I clinical trial in Boston will be closed to new patients.
This first clinical trial of EndostatinTM Protein, an angiogenesis inhibitor that seeks to reduce tumors by cutting off their blood supply, is a Phase I study in which researchers are assessing the safety and proper dosage of the drug.
"We are moving forward and enrolling the final 12 patients in this clinical trial," said Principal Investigator Donald Kufe, MD. "We began this study with the expectation of treating between 15 and 30 patients. This group will complete the Boston portion of this Phase I study of Endostatin’s clinical safety."
Patients currently on the trial may remain on the study as long as they continue to meet the requirements of the protocol, said Kufe.
Patient registration for the database will permanently close Monday, July 17 at 6 p.m., EDT. People who already have registered to be considered for the clinical trial do not need to re-register; they will remain eligible for enrollment until all 12 new participants have been selected.
Patients seeking to participate in the trial - who have not already registered - may call (617) 632-5100. Information about the trial, such as the schedule and the eligibility criteria, is also available at the web sites of Dana-Farber Cancer Institute, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center, or by fax at 1-800-772-0253.
The phone line, which is staffed by oncology nurses, will be open weekdays between 8 a.m. and 6 p.m., EDT. Callers will be asked a series of questions to help determine if they are clinically eligible for the trial.
The study is open to cancer patients, age 18 and over, with solid tumors for which no other treatment is known to provide a benefit. Patients with leukemia, lymphoma, myeloma or primary brain tumors are not eligible for this study.
The study is being conducted by Dana-Farber/Partners CancerCare — a collaboration of Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Massachusetts General Hospital — in conjunction with Beth Israel Deaconess Medical Center, a member of the CareGroup healthcare system. The sponsor for this trial is EntreMed, Inc., Rockville, Maryland.
Contact: Todd Ringler, Dana-Farber
Georgia Peirce, MGH, (617)724-6423
Vin
Petrini, Brigham and Women's, (617) 732-5216
Patti Embry-Tautenhan, Beth
Israel Deaconess Medical Center, (617) 975-6140
Recent News | News Archives | Massachusetts General Hospital